Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INCY

Incyte Corp.

Sep 13 • 04:00PM ET

63.56

Dollar change +0.20
Percentage change 0.32	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VOO VO XBI COWZ VUG RSP USMV IVV SPY

Scroll to Statements

Index	S&P 500	P/E	179.09	EPS (ttm)	0.35	Insider Own	1.21%	Shs Outstand	224.29M	Perf Week	3.75%
Market Cap	12.24B	Forward P/E	11.53	EPS next Y	5.51	Insider Trans	-2.38%	Shs Float	190.27M	Perf Month	3.89%
Income	97.30M	PEG	5.71	EPS next Q	1.27	Inst Own	104.39%	Short Float	5.68%	Perf Quarter	1.39%
Sales	3.86B	P/S	3.17	EPS this Y	-52.30%	Inst Trans	0.70%	Short Ratio	4.26	Perf Half Y	8.58%
Book/sh	15.64	P/B	4.06	EPS next Y	227.85%	ROA	1.79%	Short Interest	10.80M	Perf Year	0.73%
Cash/sh	7.89	P/C	8.06	EPS next 5Y	31.39%	ROE	2.51%	52W Range	50.27 - 70.36	Perf YTD	1.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	38.99%	ROI	3.22%	52W High	-9.66%	Beta	0.74
Dividend TTM	-	Quick Ratio	1.84	Sales past 5Y	14.55%	Gross Margin	91.40%	52W Low	26.44%	ATR (14)	1.75
Dividend Ex-Date	-	Current Ratio	1.92	EPS Y/Y TTM	-76.97%	Oper. Margin	0.87%	RSI (14)	49.86	Volatility	2.58% 2.59%
Employees	2524	Debt/Eq	0.01	Sales Y/Y TTM	9.78%	Profit Margin	2.52%	Recom	2.12	Target Price	72.78
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-325.90%	Payout	0.00%	Rel Volume	0.76	Prev Close	63.36
Sales Surprise	2.85%	EPS Surprise	-343.09%	Sales Q/Q	9.34%	Earnings	Jul 30 BMO	Avg Volume	2.54M	Price	63.56
SMA20	-0.50%	SMA50	-0.03%	SMA200	6.48%	Trades		Volume	1,937,019	Change	0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100
Aug-03-22	Downgrade	Guggenheim	Buy → Neutral
Aug-03-22	Downgrade	Evercore ISI	Outperform → In-line	$90 → $78
Jul-28-22	Initiated	Wells Fargo	Equal Weight	$76
Feb-09-22	Downgrade	SVB Leerink	Mkt Perform → Underperform	$60 → $56
Jan-18-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$78 → $90
Nov-19-21	Initiated	BMO Capital Markets	Market Perform	$75
Jul-20-21	Upgrade	The Benchmark Company	Hold → Buy	$89

Show Previous Ratings

Sep-14-24 12:45PM	Incytes CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer (Business Wire)
10:30AM	Incytes Retifanlimab (Zynyz) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium (Business Wire)
Sep-09-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-29-24 11:31AM	Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-21-24 11:40AM	Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 (Business Wire)
01:20AM	Loading…
Aug-17-24 01:20AM	Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug (Zacks)
Aug-16-24 10:33AM	Armed with Phase III win, Incyte eyes label expansion for Monjuvi (Pharmaceutical Technology)
Aug-15-24 04:30PM	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi) in Relapsed or Refractory Follicular Lymphoma (Business Wire)
12:32PM	FDA greenlights Incyte and Syndaxs GvHD drug Niktimvo (Pharmaceutical Technology)
10:11AM	FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication (Benzinga)
08:08AM	Incyte builds out its arsenal of post-transplant drugs (BioPharma Dive)
Aug-14-24 05:34PM	Incyte and Syndax Announce U.S. FDA Approval of Niktimvo (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) (Business Wire)
09:57AM	Do Options Traders Know Something About Incyte (INCY) Stock We Don't? (Zacks)
Aug-13-24 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Aug-07-24 05:00PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
02:17PM	Loading…
Jul-30-24 02:17PM	Analyst Report: Incyte Corporation (Morningstar Research)
12:57PM	Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance (Benzinga)
10:07AM	Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
09:30AM	Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:15AM	Incyte trims cancer drug pipeline in R&D refocus (BioPharma Dive)
07:13AM	Incyte: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Jul-24-24 10:26AM	Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings? (Zacks)
Jul-23-24 10:01AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-15-24 07:00PM	Analyst Report: Incyte Corporation (Morningstar Research)
02:01PM	Incyte (INCY) Gains 19.6% in Three Months: Here's Why (Zacks)
Jul-09-24 05:08PM	S&P 500 Gains and Losses Today: Albemarle Stock Pressured by Weak Lithium Prices (Investopedia)
08:00AM	Incyte to Report Second Quarter Financial Results (Business Wire)
06:53AM	The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024 (InvestorPlace)
06:00AM	Loading…
06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jul-08-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
Jul-02-24 05:27PM	S&P 500 Gains and Losses Today: Index Tops 5,500 as Powell Touts Inflation Progress (Investopedia)
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
Jun-14-24 03:00PM	Insider Sale: EVP & General Manager US Barry Flannelly Sells 19,164 Shares of Incyte Corp (INCY) (GuruFocus.com)
Jun-13-24 08:00AM	Incyte Announces Final Results of Tender Offer (Business Wire)
Jun-11-24 08:00AM	Incyte Announces Preliminary Results of Tender Offer (Business Wire)
Jun-07-24 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-24 04:05PM	Incyte Completes Acquisition of Escient Pharmaceuticals (Business Wire)
11:31AM	Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks)
May-21-24 01:15PM	Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings (Business Wire)
08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
May-17-24 12:24PM	Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week (Zacks)
May-14-24 05:00PM	Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress (Business Wire)
03:18AM	Heard on the Street Monday Recap: Hello Kitty (The Wall Street Journal)
May-13-24 05:24PM	Health Care Roundup: Market Talk (The Wall Street Journal) +8.56%
05:23PM	S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan (Investopedia)
01:49PM	Sector Update: Health Care Stocks Mixed in Afternoon Trading (MT Newswires)
12:41PM	Incyte, Squarespace rise; Chimera Investment, Amazon fall, Monday, 5/13/2024 (Associated Press Finance)
10:57AM	Incyte Stock Marks Biggest Jump in 7 Years on Dutch Auction Buyback Plan. How It Works. (Barrons.com)
09:24AM	Sector Update: Health Care Stocks Decline Pre-Bell Monday (MT Newswires)
09:14AM	Incyte Stock Jumps on Dutch Auction Buyback Plan. How It Works. (Barrons.com)
08:24AM	Incyte Launches $1.67 Billion Share Repurchase 'Dutch Auction' Tender Offer; to Buy Back $328 Million of Baker Entities' Shares (MT Newswires)
07:00AM	Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock (Business Wire)
May-12-24 08:26AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:17PM	MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-02-24 11:17PM	Q1 2024 Insight Enterprises Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
May-01-24 11:24AM	TD Cowen Adjusts Price Target on Incyte to $80 From $88 (MT Newswires)
11:12AM	Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:53AM	RBC Capital Adjusts Price Target on Incyte to $60 From $65 (MT Newswires)
10:33AM	Piper Sandler Adjusts Price Target on Incyte to $80 From $85 (MT Newswires)
10:20AM	Goldman Sachs Adjusts Price Target on Incyte to $60 From $63 (MT Newswires)
08:55AM	Leerink Partners Adjusts Price Target on Incyte to $80 From $83, Keeps Outperform Rating (MT Newswires)
07:58AM	Citigroup Adjusts Price Target on Incyte to $80 From $81 (MT Newswires)
07:50AM	BMO Capital Adjusts Incyte Price Target to $52 From $56 (MT Newswires)
Apr-30-24 04:31PM	Analyst Report: Incyte Corporation (Morningstar Research)
02:57PM	Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained (MT Newswires)
11:54AM	INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:50AM	Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
10:10AM	Incyte misses quarterly profit on weak sales of lead drug (Reuters)
09:36AM	Incyte's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed (MT Newswires)
09:30AM	Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:34AM	Incyte Corp (INCY) Q1 2024 Earnings: Misses Revenue Estimates but Shows Strong Growth in ... (GuruFocus.com)
07:10AM	Incyte: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Apr-23-24 10:12AM	Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M (FierceBiotech.com)
10:01AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
09:44AM	Incyte (INCY) to Report Q1 Earnings: What's in the Cards? (Zacks)
07:00AM	Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists (Business Wire)
Apr-15-24 05:30AM	Certain Biotech Investors Get an Early Look at Results. Is That Fair? (The Wall Street Journal)
Apr-11-24 08:00AM	Incyte to Report First Quarter Financial Results (Business Wire)
Apr-06-24 08:56AM	Biotech Executive Who Bet on Rivals Stock Committed Insider Trading, Jury Says (The Wall Street Journal)
Apr-01-24 08:30AM	Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia (Business Wire)
08:30AM	CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia (GlobeNewswire)
Mar-31-24 11:53AM	12 Best S&P 500 Stocks To Buy According to Analysts (Insider Monkey)
Mar-29-24 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-24 02:47PM	SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive (Bloomberg)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 10:37AM	MorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 11:30AM	Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report? (Zacks)
08:18AM	MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-12-24 01:52PM	Incyte (INCY) Posts Positive Results on Opzelura From HS Study (Zacks)
Mar-11-24 01:02PM	Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead (InvestorPlace)
07:18AM	Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial (FierceBiotech.com)
Mar-10-24 04:05PM	Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis (Business Wire)
04:05PM	Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura) in Patients with Mild-to-Moderate Hidradenitis Suppurativa (Business Wire)
Mar-07-24 03:00PM	3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise (InvestorPlace)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
THOMAS R TRAY	Officer	Sep 13 '24	Proposed Sale	63.37	382	24,207		Sep 13 04:06 PM
JONATHAN ELLIOTT DICKINSON	Officer	Sep 12 '24	Proposed Sale	62.36	8,450	526,930		Sep 12 04:17 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 12 '24	Sale	60.63	11,608	703,793	90,011	Aug 14 03:37 PM
STEVEN STEIN	Officer	Aug 12 '24	Proposed Sale	60.63	11,608	703,771		Aug 12 04:39 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 25 '24	Sale	70.00	15,571	1,089,970	36,701	Jul 29 03:50 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '24	Sale	64.19	1,306	83,832	58,042	Jul 17 12:24 PM
Flannelly Barry P	EVP & General Manager US	Jul 09 '24	Sale	60.00	8,148	488,880	50,534	Jul 11 12:35 PM
Flannelly Barry P	EVP & General Manager US	Jun 12 '24	Sale	60.00	19,164	1,149,840	66,377	Jun 14 12:17 PM
Tray Thomas	Principal Accounting Officer	Jun 06 '24	Sale	58.91	1,093	64,389	21,634	Jun 10 12:25 PM
BAKER BROS. ADVISORS LP	Director	May 07 '24	Option Exercise	49.01	30,000	1,470,300	33,462,981	May 09 06:25 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 03 '24	Sale	65.51	7,365	482,481	90,218	Jan 05 12:27 PM
Iyengar Vijay K	EVP, GMAPPS	Jan 02 '24	Sale	65.00	657	42,705	43,412	Jan 04 01:05 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '23	Sale	62.37	1,067	66,549	23,436	Dec 14 02:11 PM
Tray Thomas	Principal Accounting Officer	Dec 12 '23	Sale	57.36	210	12,046	24,503	Dec 14 02:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INCY

Incyte Corp.

Upgrade your FINVIZ experience